Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Royal Free and University College Medical School
With
Boehringer Ingelheim
Patients with COPD will be randomised to tiotropium or placebo in addition to their usual medication. They will be followed prospectively over 1 year and provide sputum for quantification of IL-6 and IL-8 at baseline and at 3 monthly intervals.Serum IL-6 will also be quantified at baseline and over the year. Changes in inflammatory markers will be assessed by analysis of area under the curve of log transformed data. Exacerbation frequency will be calculated from patient diary cards using a previously validated symptom-based exacerbation definition.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
diagnosis of COPD,
FEV1 \< 80% predicted,
minimum 10 pack year smoking history
You may not be if
asthma,
atopic disease,
eosinophilia,
history of malignancy,
history of clinically significant pulmonary disease
